CI Form 144 Notice: Proposed Insider Sale Totals $8.56M
Rhea-AI Filing Summary
Form 144 filing for Cigna (CI) reports a proposed sale of 28,526 common shares through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $8,557,800 and approximately 266,928,075 shares outstanding. The shares to be sold were acquired via restricted stock vesting (1,137 shares on 03/01/2024) and option exercises or option-related transactions (2,636 shares on 08/13/2024; 13,155 shares and 11,598 shares with dates shown as 08/15/2025 tied to options granted in 2018 and 2019). No securities were reported sold in the past three months. The filer attests they are not aware of any material nonpublic information.
Positive
- Complete disclosure of broker, share count, aggregate market value, and acquisition history demonstrating compliance with Rule 144
- No sales in the past three months are reported, reducing immediate concerns about a pattern of recent insider disposals
- Attestation that the filer does not possess undisclosed material adverse information
Negative
- Insider proposed sale of 28,526 shares with an aggregate market value of $8,557,800, representing meaningful insider liquidity
Insights
TL;DR: Insider plans to sell $8.56M of CI stock; filings appear routine and disclose recent option and restricted stock activity.
The notice details a proposed sale of 28,526 common shares with an aggregate market value of $8,557,800 and lists the acquisition sources: restricted stock vesting and option exercises/grants. The filing is procedural under Rule 144 and includes the required attestation about material nonpublic information. There are no reported sales in the prior three months, which suggests this transaction is not part of an ongoing high-frequency disposal pattern disclosed here. For investors, the filing documents insider liquidity but provides no operational or financial performance information.
TL;DR: Filing demonstrates compliance with disclosure rules; the attestation reduces governance-related uncertainty.
The Form 144 supplies the broker, sale timing, share counts, and acquisition history as required, including that the filer represents no undisclosed material adverse information. That representation, together with a clear breakdown of acquisition types (restricted stock vesting and option exercises), reflects adherence to disclosure protocols. The filing does not indicate any unusual arrangements or withheld information, and no prior three-month sales are reported, which is relevant for assessing insider disposal patterns.